{
    "clinical_study": {
        "@rank": "132843", 
        "arm_group": [
            {
                "arm_group_label": "Non-Caucasian", 
                "description": "Non-Caucasian male and female adult subjects (greater than or equal to 18 years of age) with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the subject's final clinical diagnosis of PD or ET."
            }, 
            {
                "arm_group_label": "Caucasian", 
                "description": "Caucasian male and female adult subjects (greater than or equal to 18 years of age) with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the subject's final clinical diagnosis of PD or ET."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine if the diagnostic performance of\n      DaTscan\u2122 single photon emission computed tomography (SPECT) imaging is different in\n      non-Caucasian subjects compared with Caucasian subjects with movement disorders."
        }, 
        "brief_title": "Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan\u2122 Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Essential Tremor", 
            "Parkinson's Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Tremor", 
                "Essential Tremor"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For Non-Caucasians:\n\n          -  Non-Caucasian male and female adult subjects (greater than or equal to 18 years of\n             age) with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT\n             imaging to assist with the subject's final clinical diagnosis of PD or ET.\n\n          -  The subject has existing diagnostic-quality and interpretable DaTscan SPECT images of\n             the brain.\n\n        For Caucasians:\n\n          -  Caucasian male and female adult subjects (greater than or equal to 18 years of age)\n             with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging\n             to assist with the subject's final clinical diagnosis of PD or ET.\n\n          -  The subject has existing diagnostic-quality and interpretable DaTscan SPECT images of\n             the brain.\n\n          -  The subject is matched by final clinical diagnosis, sex and age (\u00b15 years)  with a\n             non-Caucasian subject.\n\n        Exclusion Criteria:\n\n          -  Known/suspected structural abnormalities of the brain (e.g., hydrocephalus; brain\n             tumor; stroke; etc.) that can grossly distort the DaTscan images."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor\n        (ET)."
            }
        }, 
        "enrollment": {
            "#text": "232", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952678", 
            "org_study_id": "GE-001-011"
        }, 
        "intervention": {
            "arm_group_label": [
                "Non-Caucasian", 
                "Caucasian"
            ], 
            "description": "The subjects in this study were dosed with DaTscan drug product in a separate study.", 
            "intervention_name": "Subjects dosed in a separate study", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DaTscan", 
            "Parkinson's Disease"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08540"
                }, 
                "name": "GE Healthcare"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Retrospective Clinical Study to Compare the Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan\u2122 Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)", 
        "overall_official": {
            "affiliation": "GE Healthcare", 
            "last_name": "Igor D Grachev, M.D., PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blinded visual assessment of each subject's DaTscan\u2122  image as normal or abnormal by majority interpretation in the Blinded Image Evaluation (BIE).", 
            "measure": "Blinded visual assessment of each subject's DaTscan image as normal or abnormal", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952678"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Abnormal images will be further categorized as 1) abnormal and typical of PD, or 2) abnormal but atypical of PD.", 
            "measure": "Abnormal images categorized", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "GE Healthcare", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "H2O Clinical LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Quintiles", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}